References: 1. Sestak I, Martín M, Dubsky P, et al. Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Res Treat. [published online ahead of print April 30,2019]. https://doi.org/10.1007/s10549-019-05226-8. 2. Paik S, Tang G, Shak S, et al; Gene Expression and Benefit of Chemotherapy in Women with Node-Negative, Estrogen Receptor-Positive Breast Cancer. J Clin Oncol 2006; 24:3726-3734. 3. Albain K, Barlow W, Shak S, et al; Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomized trial. Lancet Oncol 2010;11:55-65. 4. Filipits M, Rudas M, Jakesz R, et al; for EP Investigators. A new molecular predictor of distant recurrence in ER‑positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res . 2011;17(18):6012-6020. 5. Paik S, Shak S, Tang G, et al; A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer. N Engl J Med 2004; 351:2817-26. 6. van’t Veer L, Dai H, van de Vijver M, et al; Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6. 7. Jerevall P, Ma X, Li H, et al; Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br J Cancer 2011;104:1762-1769. 8. Wallden B, Storhoff J, Nielsen T, et al; Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. BMC Medical Genomics 2015; 8:54. 9. National Comprehensive Cancer Network. Breast Cancer (Version 2.2018) https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed October 18, 2018. 10. Harris LN, Ismaila N, McShane LM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2016;34(10):1134-1150. 11. Curigliano G, Burstein H, Winer E, et al; De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer. Ann Oncol 2017;28:1700-1712. 12. Senkus E, Kyriakides S, Ohno S, et al; ESMO Guidelines Committee. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26(Suppl 5):v8-v30. 13. National Institute for Health and Care Excellence. Tumor profiling tests to guide adjuvant chemotherapy decisions in early breast cancer. http://nice.org.uk/guidance/dg34. Accessed February 26, 2019. 14. Krop I, Ismaila N, Andre A, et al; Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Foc